Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Zoetis (ZTS) Down 7.5% Since Last Earnings Report: Can It Rebound?

Zoetis has proven to investors that the pharmaceutical apple doesn't fall far from the tree.

Why Zoetis Is the Pfizer of Animal Healthcare

We upgrade Zoetis to Buy after a 14% price decline, means this multi-year compounder once again offers a low-teens annualized return.

Zoetis: Multi-Year Compounder On Sale Again After 14% Correction

This leader in animal healthcare has shown strong financial performance through the years.

Is Zoetis Still a Buy With Its Stock Near All-Time Highs?

The animal health leader continues to invest in its future.

Will Zoetis' Acquisition Spree Pay Off?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--Zoetis today announced its long-term sustainability goals.

Zoetis Launches “Driven to Care” Sustainability Initiative and Long-Term Goals to Meet Commitments to Communities, Animals and the Planet

Zoetis Inc (NYSE: ZTS) seems well-positioned in 2021 with the stock valuation offering an attractive entry point, according to BofA Securities. The Zoetis Analyst: Michael Ryskin upgraded the rating for Zoetis from Neutral to Buy, while maintaining a price target of $180.

BofA Upgrades Zoetis Stock On Business Potential, Valuation

Agree Realty

Avis Budget Group

American Assets

Incyte

Molecular Templates

OPKO Health

Royalty Pharma

Sonos

United States Lime & Minerals, Inc.

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #fortune500--Zoetis will participate in the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021.

Zoetis to Participate in the Cowen 41st Annual Health Care Conference

NextEra Energy

When it comes to stocks to buy, we are getting more selective, and that's a good thing. In fact, buying pressure in more selective stocks means they may have more profit potential going forward.

2 Fundamentally Superior Stocks I Just Rang the Register On

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. will participate in the Bank of America Securities 2021 Animal Health Summit Virtual Forum on Thursday, Feb. 25, 2021.

Zoetis to Participate in the Bank of America Securities 2021 Animal Health Summit Virtual Forum

Animal health company Zoetis Inc (NYSE: ZTS) received the European Commission's marketing approval for Solensia (frunevetmab), an injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats. Solensia targets Nerve Growth Factor (NGF), a key player in osteoarthritis pain.

Zoetis' Solensia Wins European Nod For Osteoarthritis Pain In Cats

ZAVENTEM, Belgium--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis receives European Commission marketing authorization for Solensia® (frunevetmab), a new therapy for feline osteoarthritis pain.

Zoetis Receives European Commission Marketing Authorization for Solensia® (frunevetmab), a New Therapy for Feline Osteoarthritis Pain

Zoetis Inc. (NYSE: ZTS) said on Tuesday that its revenue in the fiscal fourth quarter saw an 8% annualised growth to £1.29 billion. Its net income in Q4 stood at £258.21 million that translates to 53.94 pence per diluted share.

Zoetis says its revenue jumped 8% in the fiscal fourth quarter

Zoetis' (ZTS) CEO Kristin Peck on Q4 2020 Results - Earnings Call Transcript

Zoetis earnings and sales were better than expected, while the animal drug giant guided high for 2021. ZTS stock rose early Tuesday.

Zoetis Earnings Top, Guidance Strong; ZTS Stock Rises

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis reports fourth quarter and full year 2020 financial results.

Zoetis Reports Fourth Quarter and Full Year 2020 Results

Zoetis (ZTS) will report earnings and revenues, and provide other pipeline updates when it releases fourth-quarter 2020 results.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #dividend--Zoetis declares Q2'21 dividend.

Zoetis Declares Second Quarter 2021 Dividend

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Zoetis (ZTS) Q4 Earnings Expected to Decline

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #Forbes--Zoetis has been named one of America's Best Midsize Employers by Forbes Magazine for the fifth time.

Forbes Names Zoetis One of America's Best Midsize Employers

Corteva Inc

DuPont de Nemours

Deere & Company

Farmland Partners

IDEXX Laboratories

Gladstone Land

Starboard Value Acquisition Corp.

Investing in Agriculture Stocks: What Investors Need to Know

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #LGBTQ--Zoetis named a best place to work for LGBTQ equality.

Zoetis Scores 100% on 2021 Corporate Equality Index

Apple

AllianceBernstein Hld

Blackrock Inc

Digital Realty Trust

LM Ericsson Telefon

Prologis

TDK Corp

These are some of the top stocks to buy if you want to make a play on the growth and strength of the Chinese economy. The post 9 Hot Stocks to Buy Now to Profit off Chinese Markets appeared first on InvestorPlace.

9 Hot Stocks to Buy Now to Profit off Chinese Markets

Abbott Labs

Becton, Dickinson and Co.

AdvisorShares Focused Equity ETF

Eagle Bancorp

Globe Life Inc

HEICO

Hormel Foods

Miller Industries

RPM International

Thermo Fisher Scientific

Welcome to Alpha Trader. We have a special double bill today in honor of wildcard weekend coming up on the show. Eddy Elfenbein of Crossing Wall Street giving us his top five new stocks for 2021. But first we are pleased to welcome back to the show, Ryan Detrick. He is Chief Market Strategist for LPL Financial. Ryan, welcome back to Alpha Trader.

News for Zoetis Stock (ZTS)